NCT06930703View on ClinicalTrials.gov

Cannabidiol in Sickle Cell Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2027

Conditions
Sickle Cell Disease
Interventions
DRUG

Cannabidiol

Cannabidiol (CBD) twice daily taken orally for 4-weeks

DRUG

Placebo

Placebo equivalent twice daily taken orally for 4-weeks

Trial Locations (1)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, Manhattan

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER